Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center
2024年7月18日 - 9:30PM
Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative
LIBERTY® Endovascular Robotic Surgical System, today announces it
has received Institutional Review Board (IRB) approval and signed a
clinical trial agreement with Memorial Sloan Kettering Cancer
Center, located in New York City, New York. Memorial Sloan
Kettering Cancer Center will conduct the clinical trial as part of
the Investigational Device Exemption (“IDE”) for LIBERTY®, and the
Company expects its results will support the future marketing
submission to the FDA and subsequent commercialization.
The clinical trial at Memorial Sloan Kettering Cancer Center
will be led by Francois Cornelis, MD, PhD. “I’m a great believer in
the future of robotics for interventional procedures and the value
robotics can bring to physicians and our patients. I am excited to
participate in the LIBERTY clinical trial.” said Dr. Cornelis. Dr.
Cornelis will also serve as principal investigator for the overall
LIBERTY clinical trial.
“We are excited to have a hospital the caliber of Memorial Sloan
Kettering Cancer Center partnering with us to complete the
enrollment of the clinical sites in our trial,” commented Harel
Gadot, CEO, President and Chairman of Microbot Medical.
The Company previously announced that Brigham and Women's
Hospital in Boston, and Baptist Hospital of Miami are both enrolled
in the trial and have performed clinical cases.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
clinical- stage medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The Investigational LIBERTY® Endovascular
Robotic Surgical System aims to improve the way surgical robotics
are being used in endovascular procedures today, by eliminating the
need for large, cumbersome, and expensive capital equipment, while
reducing radiation exposure and physician strain. The Company
believes the LIBERTY® Endovascular Robotic Surgical System’s remote
operation has the potential to be the first system to democratize
endovascular interventional procedures.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of the
LIBERTY® Endovascular Robotic Surgical System, the outcome of its
studies to evaluate the LIBERTY® Endovascular Robotic Surgical
System, uncertainty in the results of pre-clinical and clinical
trials or regulatory pathways and regulatory approvals, including
whether the Company’s pivotal study in humans is successful, any
failure or inability to recruit physicians and clinicians to serve
as primary investigators to conduct regulatory studies which could
adversely affect or delay such studies, disruptions resulting from
new and ongoing hostilities between Israel and the Palestinians and
other neighboring countries, any lingering uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty
IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
過去 株価チャート
から 8 2024 まで 9 2024
Microbot Medical (NASDAQ:MBOT)
過去 株価チャート
から 9 2023 まで 9 2024